financial year 2016 annual press conference - … · •buscopan® 236 eur million (+15.1%)...

Annual Press Conference

Financial year 2016

Financial year 2016

Hubertus von Baumbach

Chairman of the Board of

Managing Directors

Strategic realignment

Boehringer Ingelheim one year ago

Animal Health

Biopharma

Prescription Medicines

Consumer Health Care

Generics

Annual Press Conference 2017 4

• Prescription medicines

• Consumer health care

• Animal health

• Biopharmaceutical contract manufacturing

• Generics

Boehringer Ingelheim today


• Human pharmaceuticals

• Animal health

• Biopharmaceutical contract manufacturing

Animal Health Human Pharmaceuticals

Biopharma- ceuticals

ONE Human Pharma

BU Human Pharma

Allan Hillgrove

Innovation Dr Michel

Pairet

Animal Health

Dr Joachim Hasenmaier

Human Resources Dr Andreas Neumann

Finance Simone Menne


CEO Hubertus

von Baumbach

Functional organisation structure

Successful financial year 2016

Financial year 2016

Simone Menne

Corporate Board Division

Finance

Net sales expectations exceeded

Net sales expectations exceeded

Net sales:

15.9 billion euros

+ 7.3%*

Operating income:

2.9 billion euros

+ 26.6%

Return on sales:

18.1% +2.8 percentage

points

*currency-adjusted


R&D expenditure:

3.1 billion euros

+3.6%

High liquidity and equity safeguard independence

10.2 12.0

+2.9 -0.1 -1.0

Financial funds

Financial funds

2016

Cash flow from operating activities

Cash flow from investing activities

Cash flow from financing activities

2015

(in EUR billion)

• Financial funds of EUR 12 billion safequard independence and financial mobility

• Cash flow from operating activities significantly exceeds investments in tangible assets



Total assets: EUR 26.1 billion

Sound equity structure:

• Equity of EUR 11.3 billion equivalent to equity ratio of 43.3%

• Tangible and intangible assets covered more than three times by equity


Assets Liabilities & Equity

Tangible assets

Other assets

Equity

Pension provisions

Other liabilities


Growth in all businesses

1.5

1.6

0.6

Others

Growth in all businesses

Sales growth of businesses (currency-adjusted):

• Prescription medicines (PM): +7.4%

• Animal health (AH): +8.5%

• Consumer health care (CHC): +5.5%

• Biopharmaceutical contract manufacturing (BIO): +6.4%

in EUR billion

CHC 12.0

PM


AH

BIO

Prescription medicines: net sales expectations exceeded

• 76% of group net sales • +7.4% (currency-adjusted) compared with previous year

• Net sales of important products,

growth currency-adjusted

• spiriva® EUR 3.0 billion (-14.9%)

• pradaxa® EUR 1.4 billion (+6.8%)

• trajenta®/jentadueto®* EUR 1.1 billion (+23.1%)

• ofev® EUR 0.6 billion (+106.4%)


in EUR billion

12.0

PM

*in collaboration with Eli Lilly and Company

Animal health: net sales outperform the market


• Net sales of important products, growth

currency-adjusted

• ingelvac circoflex® 283 EUR million (+2.9%)

• ingelvac prrs® 114 EUR million (+16.3%)

• metacam® 106 EUR million (+7.1%)

• duramune® 100 EUR million (+13.6%)

Annual Press Conferencez 2017 17

1.5

in EUR billion

AH

Consumer health care: successful final year


• Net sales of important products, growth

currency-adjusted

• dulcolax® 237 EUR million (+7.7%)

• buscopan® 236 EUR million (+15.1%)

• pharmaton® 145 EUR million (+9.8%)

• mucosolvan® 136 EUR million (-15.5%)


1.6

in EUR billion

CHC

Biopharmaceutical contract manufacturing: increase in net sales

• 4% of group net sales • +6.4% compared with previous year


0.6 BIO

in EUR billion

Asia/ Australia/Africa

4,226 million euros

+9.7%

Americas

6,542 million euros

-1.6%

Americas region records highest net sales

Europe

5,082 million euros

+19.0%*

*One-off effect from AbbVie payment included

Net sales development, currency-adjusted


Strong growth in emerging markets


+15.8% currency-adjusted

Strong contribution to European economy

Strong contribution to European economy

Source: WifOR 2016 / Basis: Financial figures 2014 Annual Press Conference 2017 23

Multiplier for additional jobs

in the EU 8.5

billion euros gross value added

Improvements to operating conditions in Germany needed

Improvements to operating conditions in Germany needed


34% of global

workforce

38% of global R&D

spendings

42% of total investments

6% of total net

sales

Corporate development

Hubertus von Baumbach

Chairman of the Board of

Managing Directors

2,338

5,533

10,891 12,036

1993 2003 2013 2016

Sustainable success achieved

Net sales of prescription medicines in millions of euros

*in collaboration with Eli Lilly and Company


*

*

*

*

*

*

Success through change

Animal health: repositioned with Merial

More than

10,000 employees

Products in more than

150 markets

Presence in

99 countries

Animal health: strong together


Animal health: outgrowing the market on a sustainable basis

Targets:

• Completing successful integration

• More than doubling Animal Health net sales through Merial integration in 2017

• Outgrowing market on a sustainable basis

• In future investing 8-10 per cent of Animal Health net sales in R&D


Human pharmaceuticals: further growth with strong therapeutic areas


• Respiratory diseases

• Cardiometabolic diseases

• Oncology

• Diseases of the central nervous system

• Immunology



jardiance®* reduces relative risk of dying from cardiovascular diseases among patients with type 2 diabetes and pre-existing cardiovascular diseases by more than one third.


*in collaboration with Eli Lilly and company


praxbind® reverses the effect of the pradaxa® oral anticoagulant in just a few minutes



spiolto® respimat® - our further development for the treatment of chronic obstructive pulmonary disease (COPD)



ofev®, for the treatment of idiopathic pulmonary fibrosis, market leader in many countries - to date some 25,000 patients treated



giotrif® for the treatment of lung cancer with an EGFR mutation


Human pharmaceuticals: providing patients with new solutions

• Diabetes: jardiance®* to treat chronic heart failure with and without diabetes

• Oncology: nintedanib for the treatment of mesothelioma

• Nintedanib in further fibrotic diseases

• Biosimilars: biosimilar candidates in oncology and immunology

• Immunology: approval of IL-23 inhibitor** expected in 2019

*in collaboration with Eli Lilly and company **in partnership with AbbVie


Human pharmaceuticals: early research projects

• Research into secondary diseases in diabetes and CNS diseases

• New area immuno-oncology

• More partnerships with universities, scientific institutes and biotech companies

• Research outside our indication areas – “Research beyond borders”

• Get involved in early technologies via Boehringer Ingelheim Venture Fund


41

Major investments in biopharmaceutical production capacity

Major investments in biopharmaceutical production capacity

• Many decades of competence in biopharmaceutical contract manufacturing

• Investment of almost 700 million euros, including infrastructure, in Vienna biopharmaceutical site


Foundations laid for further growth

Outlook for financial year 2017

• 2017 significant increase in currency-adjusted net sales expected


Continuing to create value through innovation

Bilanzpressekonferenz 2017

Annual Press Conference

Financial year 2016

financial year 2016 annual press conference - … · •buscopan® 236 eur million (+15.1%)...

Documents